What are the indications of the COZING-USBE photodynamic laser ?
- Menieres disease, is a disorder of the inner ear that causes severe dizziness (vertigo), ringing in the ears (tinnitus), hearing loss, and a feeling of fullness or congestion in the ear. Ménière's disease usually affects only one ear.
- Vertigo (often severe and incapacitating)
- Fluctuating hearing loss
What's the technical parameter of the photodynamic natural treatment for tinnitus?
|
Laser Medium: |
GaAlAs Semiconductor aser |
|
Treatment Method: |
Laser Physiotherapy |
|
Laser wavelength: |
650nm |
|
Laser Penetration: |
1-3cm |
|
Product Package Dimension: |
15*15*10cm |
|
Model number: |
COZING-USBE |
What are the advantages of the COZING-USBE photodynamic laser ?
1. No adverse reactions, completely non-invasive.
2. Compact and portable design allows for convenient use anywhere.
3. Achieves a treatment success rate of approximately 90%.
4. superior quality.
5. No need for a main unit; simply connect directly to a power source.
6. Backed by rigorous clinical trials and certified by CFDA and CE for assurance of effectiveness.
How does the COZING-USBE photodynamic laser work?
Laser energy in the red and near infrared light spectrum is capable of penetrating tissue. It stimulates mitochondria in the cells to produce energy through the production of ATP (adenosine triphosphate). Mitochondria are the power supplies of all cells; they metabolize (burn) fuel and produce energy for the cell in the form of ATP. In stimulating the mitochondria, laser therapy can repair damaged tissue and return cells to a healthy state, reversing many degenerative conditions.
We know the importance of cell mitochondria from our investigations of neurotoxins and what can be used to reverse their effects. ALC and ALA reduce age-associated deterioration in auditory sensitivity and improve cochlear function. This effect appears to be related to the mitochondrial metabolite ability to protect and repair age-induced cochlear damage, thereby unregulating mitochondrial function and improving energy producing capabilities
Product display
Photodynamic laser Clinical Study:
Objective: This study aims to evaluate the effectiveness of low-level laser therapy (LLLT) in managing Ménière's disease (MD).
Materials and Methods: Twenty individuals diagnosed with unilateral MD and experiencing uncontrolled vertigo were enrolled. Participants were randomly assigned to two groups: Group 1 received daily LLLT sessions lasting 20 minutes using a 5-mW soft laser for 6 months, while Group 2 received betahistine at a dose of 16 mg twice daily for the same duration. Vertigo control, as per the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) guidelines, was assessed based on the number and duration of vertigo spells per month in the 6 months pre-treatment compared to the 6 months during therapy. Additionally, audiometric evaluations were conducted before and after treatment, with results reported as the pure tone average across frequencies of 500, 1000, 2000, and 3000 Hz. Assessments were conducted at baseline, and after 3 and 6 months of therapy.
Results: Both groups exhibited significant reductions in the number and duration of vertigo spells compared to baseline, with statistical significance observed at the 3-month mark in both groups (p<0.05 using multiple pair comparison test). Betahistine demonstrated faster action in reducing vertigo spells (p<0.05 when comparing 3-month results between groups). However, there was no statistically significant difference in audiometric outcomes between the two groups.
Conclusions: Our findings suggest that LLLT may effectively alleviate vertigo spells associated with MD, although its onset of action appears slower compared to betahistine. The dosage of therapy may play a role in its therapeutic effects, with increased blood flow to the inner ear being proposed as the primary mechanism underlying its efficacy.
FAQ
